Related Experiment Video
Updated: Jun 9, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case
Mehdi Loukhnati1,2, Benjamin Hebraud2, Marine Cazaux2
1Faculty of Medicine and Pharmacy, Department of Hematology, Mohammed VI University Hospital, Cadi Ayyad University, Marrakesh, Morocco, uca.ma.
None:
Prolonged and refractory hematotoxicity is a severe complication of anti-BCMA CAR-T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed. We report the case of a 55-year-old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post-CAR-T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)